BioVersys AG
BIOV
Company Profile
Business description
BioVersys AG is a multi-asset, clinical-stage biopharmaceutical company. The Group focuses on research and development of novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The pipeline products of the company include BV100 - novel MoA, Alpibectir - novel potentiator MoA, BV200 - novel anti-virulence MoA, BV500 - novel series, and others. It has one operating segment focusing on the research and development and prospective commercialization of antibiotics. Geographically, the company operates in Switzerland and France.
Contact
c/o Technologiepark
Hochbergerstrasse 60c
BaselCH-4057
CHET: +41 615515120
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
29
Stocks News & Analysis
stocks
Going into earnings, is Microsoft stock a buy, a sell, or fairly valued?
Microsoft’s earnings report is expected to touch on AI adoption and monetization.
stocks
World’s largest miner overvalued after solid quarter
The ongoing war is likely to keep commodity prices even more volatile than usual until it is resolved.
stocks
Hidden value in an expensive ASX
How investors can uncover value beyond the index heavyweights.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,024.20 | 27.20 | -0.30% |
| CAC 40 | 8,198.69 | 42.26 | 0.52% |
| DAX 40 | 24,146.90 | 48.00 | -0.20% |
| Dow JONES (US) | 49,490.03 | 340.65 | 0.69% |
| FTSE 100 | 10,436.52 | 39.94 | -0.38% |
| HKSE | 25,905.77 | 257.47 | -0.98% |
| NASDAQ | 24,657.57 | 397.60 | 1.64% |
| Nikkei 225 | 59,140.23 | 445.63 | -0.75% |
| NZX 50 Index | 12,884.93 | 60.67 | -0.47% |
| S&P 500 | 7,137.90 | 73.89 | 1.05% |
| S&P/ASX 200 | 8,793.40 | 26.10 | -0.30% |
| SSE Composite Index | 4,093.25 | 13.01 | -0.32% |